Skip to main content
    C

    Collplant Biotechnologies Ltd (CLGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.64
    +0.00 (+0.00%)

    Market Cap: $14.27M

    Last updated: Nov 16, 2026 at 4:00 PM ET

    Collplant Biotechnologies Ltd (CLGN) Statistics

    Updated Nov 16, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Collplant Biotechnologies (CLGN) has a market cap of $14.27M. It kept -3934.91% of revenue as net income over the last 12 months. Its share count is up 21.83% from a year earlier.

    Total Valuation

    Market Cap$14.27M
    Close (Nov 16, 2026)$4.64

    Key Dates

    The next earnings report is expected on Nov 24, 2026, covering the quarter ending Sep 30, 2026.

    Next Earnings DateNov 24, 2026 (expected)
    Last Earnings DateSep 30, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 4.94% in the quarter ended Jun 30, 2026 and grew 12.22% a year over 2 years.

    Shares Outstanding1.44M
    Shares Change (YoY)+21.83%
    Shares Change (QoQ)+4.94%
    Share Count Growth (2Y CAGR)+12.22%

    Valuation Ratios

    Sales and book value multiples are 21.0x and 2.3x.

    P/S Ratio21.0x
    Forward P/S2.3x
    P/B Ratio2.3x
    P/TBV Ratio2.3x

    Price Statistics

    The stock is down 76.57% over 52 weeks and trades 19.28% above its 50-day average.

    Beta (1Y)1.39
    52-Week Change-76.57%
    1-Month Change+28.00%
    3-Month Change+47.58%
    6-Month Change+6.72%
    5-Year Change-98.12%
    Total Return (1Y)-76.57%
    Total Return (3Y CAGR)-55.34%
    Total Return (5Y CAGR)-52.27%
    Return vs SPY (1Y)-89.98%
    Max Drawdown (1Y)-87.82%
    Max Drawdown (3Y)-95.96%
    Sharpe Ratio (1Y)-1.21
    Correlation with SPY (1Y)0.15
    50-Day Average$3.89
    200-Day Average$4.40
    52-Week Range$2.64 to $22.50
    RSI (14 Days)61.5
    Average Volume (20 Days)38.59K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.57x current liabilities.

    Current Ratio1.57x
    Quick Ratio1.35x

    Returns and Efficiency

    Return on equity is -424.89% over the last 12 months, against a 5-year average of -77.79%.

    Return on Equity (ROE)-424.89%
    Return on Assets (ROA)-173.86%
    Return on Capital Employed (ROCE)-262.43%
    ROE (5Y Average)-77.79%
    ROA (5Y Average)-52.04%
    ROIC (5Y Average)-59.57%
    Asset Turnover0.03x
    Inventory Turnover3.24x
    Receivables Turnover2.55x
    Cash Conversion Cycle173 days

    Scores

    CLGN has an Altman Z-Score of -29.86, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-29.86
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $318.00K over the last 12 months is down 86.76% from the 12 months before.

    Revenue$318.00K
    Revenue Growth (YoY)-86.76%
    Gross Profit-$1.66M
    Operating Income-$12.40M
    Pretax Income-$12.51M
    Net Income-$12.51M
    EBITDA-$11.52M
    EBIT-$12.36M
    Reported EPS (TTM)-$2.64

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 40.83% of the $7.20M in total assets.

    Cash and Equivalents$2.95M
    Working Capital$1.41M
    Shareholder Equity$2.94M
    Tangible Book Value$2.90M
    Total Assets$7.20M
    Total Liabilities$4.25M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $94.03K of capital spending, operating cash flow left -$11.70M of free cash flow.

    Operating Cash Flow-$11.61M
    Capital Expenditures$94.03K
    Free Cash Flow-$11.70M
    FCF Per Share-$3.80
    Depreciation and Amortization$846.00K

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -3900.94%.

    Gross Margin-521.70%
    Operating Margin-3900.94%
    Pretax Margin-3934.91%
    Net Margin-3934.91%
    EBITDA Margin-3621.70%
    EBIT Margin-3887.74%
    FCF Margin-3679.61%

    Growth

    Revenue grew 99.41% a year over 3 years.

    Revenue Growth (3Y CAGR)+99.41%
    Revenue Growth (5Y CAGR)-17.32%

    Revenue and profit by year

    Dividends and Yields

    CLGN does not pay a dividend. Its free cash flow yield is -174.81%.

    FCF Yield-174.81%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-10 reverse split on Sep 4, 2026.

    Last Split DateSep 4, 2026
    Split TypeReverse split
    Split Ratio1:10

    Peer Position

    Against 6 similar companies, CLGN has the highest P/S.

    P/S Ratio21.0x vs 4.3x median
    Revenue Growth (Trailing 4 Quarters, YoY)-86.76% vs -47.96% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 11.03% a year over the next 5 fiscal years.

    Revenue Growth Forecast (5Y CAGR)+11.03%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CLGN

    What is CLGN's market cap?

    Collplant Biotechnologies has a market cap of $14.27M.

    How many shares of CLGN are outstanding?

    Collplant Biotechnologies has 1.44M shares outstanding. The count is up 21.83% from a year earlier.

    Does CLGN pay a dividend?

    No. Collplant Biotechnologies does not pay a dividend.